In a report released today, Scott Henry from Roth Capital reiterated a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4.50. The company’s shares opened today at $2.10.
According to TipRanks.com, Henry is ranked 0 out of 5 stars with an average return of -3.1% and a 41.8% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Avadel Pharmaceuticals plc, and Novelion Therapeutics Inc.
BioDelivery has an analyst consensus of Moderate Buy, with a price target consensus of $3.83.
The company has a one year high of $3.10 and a one year low of $1.50. Currently, BioDelivery has an average volume of 498.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.